Condition (MeSH)
Lipodystrophy, Familial Partial
ClinicalTrials.gov lists 20 trials for Lipodystrophy, Familial Partial or a narrower condition beneath it. Regeneron Pharmaceuticals has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Lipodystrophy, Familial Partial itself; the rest are tagged with a narrower condition beneath it.
When did Lipodystrophy, Familial Partial trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lipodystrophy, Familial Partial trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 3 |
| Not applicable | 6 |
| Observational | 5 |
How many Lipodystrophy, Familial Partial trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 5 |
| Completed | 11 |
| Terminated | 2 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lipodystrophy, Familial Partial trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 3 |
| Akcea Therapeutics | 2 |
| Chiesi Farmaceutici S.p.A. | 1 |
| PatientCrossroads | 1 |
Which drugs are being tested for Lipodystrophy, Familial Partial? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Mibavademab | 3 |
| Metreleptin | 2 |
| Obeticholic Acid | 1 |
| Volanesorsen | 1 |
| Vupanorsen | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bood and urine sampling | 1 |
| citrate of caffeine | 1 |
| Biopsy | 1 |
| Biological analysis | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lipodystrophy, Familial Partial trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pancreatitis acute | 5 | 3 |
| Abdominal pain | 2 | 1 |
| Angina pectoris | 2 | 2 |
| Back pain | 2 | 1 |
| Pancreatitis | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lipodystrophy, Familial Partial? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Epicardial adipose tissue measurement is an interesting biomarker for cardiovascular health in a case control study of patients with familial partial type 2 lipodystrophy. | Diabetes & metabolism | 2026 | Yes |
| Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. | The Journal of clinical endocrinology and metabolism | 2019 | Yes |
| Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety. | The Journal of clinical endocrinology and metabolism | 2012 | Yes |
| Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. | Pathology | 2019 | No |
| Genetics of lipedema: new perspectives on genetic research and molecular diagnoses. | European review for medical and pharmacological sciences | 2019 | No |
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Familial partial lipodystrophy | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Familial partial lipodystrophy | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Familial partial lipodystrophy | Point prevalence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Familial partial lipodystrophy | 98306 | Exact | Orphadata Science knowledge files, Product 1 |
| Familial partial lipodystrophy | 98306 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.